全文获取类型
收费全文 | 2347034篇 |
免费 | 169115篇 |
国内免费 | 4715篇 |
专业分类
耳鼻咽喉 | 31668篇 |
儿科学 | 73161篇 |
妇产科学 | 63047篇 |
基础医学 | 333868篇 |
口腔科学 | 69959篇 |
临床医学 | 209952篇 |
内科学 | 456549篇 |
皮肤病学 | 52084篇 |
神经病学 | 182454篇 |
特种医学 | 89224篇 |
外国民族医学 | 319篇 |
外科学 | 361262篇 |
综合类 | 52516篇 |
现状与发展 | 4篇 |
一般理论 | 734篇 |
预防医学 | 170406篇 |
眼科学 | 56032篇 |
药学 | 174961篇 |
10篇 | |
中国医学 | 5883篇 |
肿瘤学 | 136771篇 |
出版年
2019年 | 17663篇 |
2018年 | 25862篇 |
2017年 | 19834篇 |
2016年 | 21892篇 |
2015年 | 24970篇 |
2014年 | 34371篇 |
2013年 | 50229篇 |
2012年 | 69371篇 |
2011年 | 73011篇 |
2010年 | 43265篇 |
2009年 | 40704篇 |
2008年 | 68758篇 |
2007年 | 72851篇 |
2006年 | 73770篇 |
2005年 | 70445篇 |
2004年 | 68164篇 |
2003年 | 64896篇 |
2002年 | 62826篇 |
2001年 | 125355篇 |
2000年 | 128483篇 |
1999年 | 106485篇 |
1998年 | 27231篇 |
1997年 | 23816篇 |
1996年 | 23925篇 |
1995年 | 22872篇 |
1994年 | 20962篇 |
1993年 | 19410篇 |
1992年 | 80824篇 |
1991年 | 77837篇 |
1990年 | 74994篇 |
1989年 | 72398篇 |
1988年 | 65888篇 |
1987年 | 64262篇 |
1986年 | 60502篇 |
1985年 | 57522篇 |
1984年 | 41975篇 |
1983年 | 35745篇 |
1982年 | 19673篇 |
1979年 | 37265篇 |
1978年 | 25574篇 |
1977年 | 21786篇 |
1976年 | 19951篇 |
1975年 | 21292篇 |
1974年 | 25809篇 |
1973年 | 24725篇 |
1972年 | 23102篇 |
1971年 | 21548篇 |
1970年 | 20223篇 |
1969年 | 18912篇 |
1968年 | 17517篇 |
排序方式: 共有10000条查询结果,搜索用时 9 毫秒
41.
42.
43.
Glauber T Silva Alejandro C Frery Mostafa Fatemi 《Computerized medical imaging and graphics》2006,30(5):321-327
We study the image formation of vibro-acoustography systems based on a concave sector array transducer taking into account depth-of-field effects. The system point-spread function (PSF) is defined in terms of the acoustic emission of a point-target in response to the dynamic radiation stress of ultrasound. The PSF on the focal plane and the axis of the transducer are presented. To extend the obtained PSF to the 3D-space, we assume it is a separable function in the axial direction and the focal plane of the transducer. In this model, an image is formed through the 3D convolution of the PSF with an object function. Experimental vibro-acoustography images of a breast phantom with lesion-like inclusions were compared with simulated images. Results show that the experimental images are in good agreement with the proposed model. 相似文献
44.
This study was undertaken to test the effect of sequential administration of an opioid and intravenous cholecystokinin (CCK) on gallbladder ejection fraction. METHODS: Forty-nine patients who had received an opioid underwent quantitative cholescintigraphy with octapeptide of CCK (CCK-8). Gallbladder ejection fraction and CCK-8-induced paradoxical filling were calculated. RESULTS: In the basal state, more of the hepatic bile entered the gallbladder (67%) than the small intestine (33%). After CCK-8 infusion, gallbladder ejection fraction was low in 37 (76%) of 49 patients and normal in 12 (24%). All 5 types of opioids lowered ejection fraction. CCK-induced paradoxical filling of the gallbladder was noted in 7 patients, but only one showed paradoxical filling of greater than 20% and none had a normal gallbladder ejection fraction. The lowering effect of opioids on gallbladder ejection fraction may last as long as 18 h after intake. CONCLUSION: CCK-8 produced a normal gallbladder ejection fraction in 24% of patients who had received an opioid and thus could exclude both acute and chronic cholecystitis during a single hepatobiliary study. 相似文献
45.
46.
47.
48.
A Kotsiou M Tsamouri S Anagnostopoulou M Tzivras E Vairactaris C Tesseromatis 《European journal of drug metabolism and pharmacokinetics》2006,31(2):97-101
Liver disease alters the pharmacokinetic and pharmacodynamic properties of hepatically eliminated drugs. The main factors influenced are plasma albumin levels, enzyme balance (induction & inhibition) and drug binding to tissue proteins. The influence of lidocaine on serum, heart and liver propranolol levels in Wistar rats after liver injury induced by carbon tetrachloride CCl4 0.4 ml/kg x 2/wkl, was investigated. 40 male Wistar rats were divided into four groups (I, II, III, IV; n=10), Group I animals received only propranolol (labelled + cold substance) 40 mg/kg/12 h p.o., group II propranolol plus lidocaine in a single dose of 4mg/kg s.c., group III was treated with CCl4 for 6 weeks and received propranolol x2 at the same dosage as group I, while group VI was treated with CCl4 and the same drug dosage as group II. The simultaneous administration of H3-propranolol and lidocaine increased propranolol levels in the serum and tissues. The liver in damaged animals showed an increase of propranolol level under lidocaine co-administration, probably due to CCl4 induced liver enzyme activity, resulting in a rapid propranolol metabolism or to competition between both drug protein binding sites. The increased propranolol levels in the heart after lidocaine administration were probably due to attributed to its high affinity for heart tissue. Consequently, as regards the therapeutic approach for patients with liver disease receiving propranolol their propranolol dosage should be reduced when lidocaine is co-administered. 相似文献
49.
A-C Koschker M Fassnacht S Hahner D Weismann B Allolio 《Experimental and clinical endocrinology & diabetes》2006,114(2):45-51
BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and highly malignant tumour with a poor prognosis. Patients present with signs of steroid hormone excess (e.g., Cushing's syndrome) or symptoms due to an abdominal mass. DIAGNOSIS: In case of an adrenal mass, hormonal workup before surgery is required for differential diagnosis, perioperative management, and for follow-up. The imaging of choice is CT or MRI with MRI being of additional use when invasion of big vessels is suspected. Apart from that, the use of 18-FDG-PET is becoming increasingly established. TREATMENT: Surgical resection is the therapeutic option of choice in stages 1 - 3. In stage 4, the adrenolytic compound mitotane is part of the first-line treatment, but often needs to be combined with cytotoxic chemotherapy. Most patients will eventually have a recurrence, so adjuvant treatment (mitotane/tumour bed radiation) has to be considered in high risk patients, even if randomized controlled trials on adjuvant treatment are still lacking. STRUCTURAL PROGRESS: Several national and European structures have recently been established in order to increase our knowledge of ACC, improve therapeutic options and diagnostic procedures, and promote research. GANIMED, as a Germany-wide network of experts on adrenal diseases, has been founded allowing for improved gathering of data and joint studies. ENSAT (European Network for the Study of Adrenal Tumours) has been brought to life, aiming at European standards for therapy, diagnosis and tumour banking. Since 2003, patients can be enrolled in the German ACC Registry. France and Italy have also developed a central registry to collect nationwide data from patients with ACC. For the first time, patients with metastatic/unresectable ACC can participate in a prospective controlled randomized trial comparing two different cytotoxic chemotherapy regimes (FIRM-ACT). 相似文献
50.
T C Friedman 《Experimental and clinical endocrinology & diabetes》2006,114(7):356-360
The overnight one-mg dexamethasone suppression test has been used for many years to screen for Cushing's syndrome. This test has usually been evaluated in controls versus patients with severe hypercortisolism. Under these conditions, the overnight dexamethasone suppression test has been reported to have high sensitivity and specificity. The objective of this study was to determine the sensitivity of the one mg overnight dexamethasone suppression test in patients with mild and/or periodic Cushing's syndrome. Therefore, an overnight dexamethasone suppression test was performed in 17 consecutive patients presenting to an endocrinology clinic with signs and symptoms of hypercortisolemia who were later proven to have Cushing's syndrome. The majority of patients were found to have both mild and periodic hypercortisolism. One mg of dexamethasone was given at midnight and a plasma cortisol was measured by radioimmunoassay at 08:00 the following morning. Using a cut-off for a morning cortisol following overnight dexamethasone of > 5 microg/dL, only three of 17 patients failed to suppress to a value less than this cut-off (sensitivity 18 %). A cut-off of > 2 microg/dL gave similar sensitivity. Even with a stringent cut-off point of > 1.8 microg/dL, only seven of 17 patients failed to suppress to a value less than this cut-off point (sensitivity of 41 %). These results demonstrate that the great majority of patients with mild and/or periodic Cushing's syndrome suppress to overnight dexamethasone. Since patients with mild and/or periodic Cushing's syndrome are the patients in whom the identification of hypercortisolism is difficult, our results from this relatively small study suggest that this test should no longer be used to exclude these patients from further workup for Cushing's syndrome. 相似文献